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Introduction 
The beginnings of labor (delivery) pains, 
before 37 weeks,   are   considered   as                                              
premature labor which is one of the most 
common causes of the infant mortality (1). 
A B S T R A C T  
Premature labor is responsible for almost 75% of all neonatal deaths and cause 
50% of childhood neurological complications. Postponing the treatment of 
preterm labor and delivery, increased infant survival and better quality of life and 
is reduce costs of care for premature infants. The aim of this study was to 
compare the effect of Indomethacin and magnesium sulfate to prevent preterm 
labor. In a clinical trial study that performed in Department of Obstetrics & 
Gynecology of Tabriz University of Medical Sciences on patient with preterm 
labor, the effects of Indomethacin and magnesium sulfate to prevent preterm 
labor, evaluated. Mean time interval between beginning of pain to patient labor in 
Indomethacin group was 83.01 ± 91.53 hour and mean time interval between 
beginning of pain to patient labor in Magnesium Sulfate group was 83.76 ± 
127.42 hour that significant difference was not found in  mean time interval 
between beginning between both groups(P=0.968). In our study, Magnesium 
Sulphate in 32% and 60% of patients was caused to delayed delivery of more 
than 24 and 48 hours  and Indomethacin in 37% and 63% of Patients was caused 
to delayed delivery of delayed delivery was more than 24 and 48 hours. Mean of 
first minute Apgar of case group (Indomethacin) was significantly more than 
mean of first minute Apgar in Control group and significant difference was not 
found in Mean of first minute Apgar between case and control groups. 41 of 
neonates in Case group and 47 of neonates in control group were alive. Our 
study, Indomethacin was effective in reducing preterm labor and as, Magnesium 
Sulphate has beneficial effects. Also, no significant differences was found in 
terms of fetuses born at birth between the two groups (P=0.294). 
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30-35% of the preterm labor due to obstetric 
indications, 40-45% due to the spontaneous 
preterm labor and 30-35% occur after 
preterm rupture of membranes.  
The reasons leading to preterm labor have 
several characteristics which often have 
interaction with each other, and also there 
are several factors contribute to their 
occurrence. These complexities make it 
difficult to efforts in order to prevent and 
treat this problem. This is especially obvious 
in the case of preterm rupture of membranes 
and spontaneous preterm labor which cause 
the 70-80% of preterm labors (1-2).  
In the most cases, the preterm labor happens 
fallowed by the spontaneous labor. 
According to reports, previous preterm 
delivery is the strongest indicator of the risk. 
It is estimated that the incidence of preterm 
delivery increases up to 14.3% following the 
first labor and it would reach to 28% after 
the second birth (3).  
Whereas it is difficult to early distinguish 
between real (true) and false labor before the 
effacement and observable dilation in the 
cervix so the utter attention to the uterine 
activity might be misleading. These 
contractions described as painful or painless, 
irregular non-rhythmic contractions could 
considerably interfere with the diagnosis of 
the real preterm labor. In women who 
experience the preterm labor, the uterus 
activities are attributed to the Braxton Hicks 
contractions in relatively rare cases. 
Whereas the uterine contractions might 
individually be misleading it might 
incorrectly diagnosis as a false labor. In 
addition to the painful or painless uterine 
contractions, it has been experimentally 
noticed that the symptoms such as pelvic 
pressure, severe cramps similar to menstrual 
cramps, watery vaginal discharge and back 
pain are associated with the imminent 
preterm labor. Iams and colleagues (1994) 
found that the warning signs and symptoms 
of preterm labor such as uterine contractions 
occur only during the 24 hours prior to 
preterm labor (1).   
The major cause of premature death is the 
respiratory distress syndrome, necrotizing 
enterocolitis (NEC), intracranial 
hemorrhage, seizures and septicemia (2). 
Since this problem involves a wide range of 
the fetal-neonatal disorders such as cardiac 
pulmonary abnormalities, nervous and 
gastrointestinal diseases so the importance 
of efforts to prevent the problem would be 
obvious (2).  
Different therapeutic techniques have been 
evaluated to prevent the preterm labor.   All 
of which are to delay preterm labor and 
reducing neonatal infection (3). Although 
the prevention of preterm labor has been 
difficult and unattainable goal; but the recent 
reports indicate that it could be achieved in 
some specific populations. The women with 
the risk of preterm labor and the women 
hospitalized with the labor preterm 
symptoms are considered as candidates for a 
number of medical interventions in order to 
improve the neonatal outcomes (2).  
In the absence of fetal or maternal 
indications for immediate labor, the medical 
interventions would be applied in order to 
prevent preterm labor; nevertheless these 
interventions are not necessary in all cases 
and in the best case, some of these 
interventions lead to relative improvement 
and also the influence of others has not been 
established. It is believed that by delaying 
the time of delivery, further improvement is 
achieved due to fetal maturation. On the 
other hands, this delay provides enough time 
for complementary therapies which improve 
clinical neonatal outcomes. In 1998, the 
American College of Obstetrics and 
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Gynecologists recommended that in the 
cases where the uterine contractions are 
associated with the cervical dilation and 
effacement, the tocolytics therapy should be 
applied (1-2).  
Tocolytics drugs include magnesium sulfate, 
Nifedipine, Ritodrine, NSAID, nitroglycerin 
and atosiban however there are different 
results listed in order to the efficiency of the 
above methods especially tocolytics drugs. 
The American College of Obstetricians and 
Gynecologists has concluded that tocolytics 
agents do not result in significant 
prolongation of pregnancy but they could 
postpone childbirth for at least 48 hours in 
some women.    
The prostaglandin inhibitors have been 
significantly taken into consideration since 
prostaglandins are involved in large natural 
labor contractions.  The antagonists would 
affect by inhibiting the production of 
prostaglandins or blocking their function in 
the target organs. The group of enzymes 
collectively called prostaglandin synthesize, 
are responsible for the conversion of free 
arachidonic acid to prostaglandins. Some 
medicines such as acetyl Salsylatha and 
Indomethacin could block this system. 
Indomethacin is used to treat preterm labor 
in some studies and If it is taken up to 24-32 
weeks of pregnancy and discontinued 72 
hours prior to delivery, this drug wouldn't be 
harmful to the mother and fetus (4). In a 
study, it has been reported that 
Indomethacin is the only drug that could 
lead to labor delaying for more than 7 days 
(5).  
By the possibility of the positive impacts of 
this drug in order to increase the labor delay 
and the usage of the Indomethacin, the 
followings are expected: 
The significant decrease in maternal and 
neonatal complications caused by the 
preterm labor and its costs.  
Considering the importance of this issue and 
consequences originating from preterm birth 
and the controversy that has been found in 
the effectiveness of the administered drugs 
especially Indomethacin, this study would 
be conducted to determine above impact on 
preterm labor and the aim of this study was 
to compare the effect of Indomethacin and 
magnesium sulfate on the prevention of 
preterm labor.  
Materials and methods  
In a clinical trial conducted on patients with 
preterm labor in the Department of 
Obstetrics and Gynecology, at Tabriz 
University of Medical Sciences, the impacts 
of Indomethacin and magnesium sulfate to 
stop preterm labor were evaluated and 
compared.  
In this study, we have selected and enrolled 
the singleton pregnant women between 28 
and 32 weeks of pregnancy who hospitalized 
with initial primary diagnosis of preterm 
labor. First of all, the consent was obtained 
from participants based on randomly placed 
in each of the two intervention groups. 
Patients were matched based on their 
maternal age and gestational age, parity and 
cervical dilatation rates, then the uterine 
contractions of the patient was examined by 
a gynecologist assistant for about 20 minutes 
following the fetal heart rate auscultation.   
The inclusion criteria were as follows:  
At least two uterine contractions were 
happened for 30 seconds during 10 minutes, 
the cervical dilatation rate was less than 5-6 
cm, the cervical effacement were observed 
as 60% -50% or less with the soft cervical 
consistency.  
Exclusion criteria were as follows  
PROM (premature rupture of membranes), 
vaginal bleeding, dilatation greater than 5 
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cm, fetal heart rate turbulence, known 
sensitivity to Indomethacin and tocolytics 
therapy, kidney failure and gastrointestinal 
bleeding. The patients were hydrated with 
normal saline solution after resting. Then the 
12 mg of   ampoule Betamethasone 
were intramuscularly injected and in the 
absence of preterm labor, a second dose of 
Betamethasone was repeated after 24 hours. 
The patients were randomly assigned in one 
of the two study groups. 4 g of magnesium 
sulfate 50% was intravenously injected to 
the control group during 20 minutes. Then 2 
g of intravenous infusions was injected once 
in an hour and this process was continued 
until the reduction or cessation of uterine 
contractions. The Indomethacin suppository 
(50 mg) was initially administered and then 
it was repeated every six hours for 24 hours. 
The monitoring was performed by fetal heart 
rate auscultation every half hour. Also the 
NST was performed to monitoring the health 
of fetus 6 hours after the cessation of the 
uterine contractions. The basic fetal heart 
rate and fetal heart rate variability was 
assessed in the NST. Due to the potential 
risk of adverse outcomes such as 
oligohydramnios after taking Indomethacin, 
Ultrasound was performed in all patients 24 
hours after cessation of the uterine 
contractions among the patients.  
In this study the sampling was randomly 
performed. According to the error type 1 
(0.05) and the error type 2 (0.2) and the 
power of test as 80%, the 75 cases were 
determined for each group.   
This clinical trial was registered in IRCT.ir 
with the number of 
(IRCT2013062613777N1).  
Results and Discussion  
In this study the results of monitoring on the 
women with the preterm labor who 
experienced the tocolytics therapy by use of 
the Indomethacin or magnesium sulfate, 
were compared with data obtained from the 
control group.   
Demographic findings of patients are shown 
in table I. Among the cases and control 
group, the average intervals between the 
start of pains and the true labor were 
respectively 83.01 ± 91.53 and 83.76 ± 
127.42 (P=0.968).  
Among the studied group, the maternal 
uterine contractions were respectively 
inactive and active at the birth moment of 46 
and 24 infants and among the control group, 
the maternal uterine contractions were 
respectively inactive and active at the birth 
moment of 50 and 20 infants (P=0.466). 
Corticosteroid dose was just completed in 46 
infants of studied group and 47 infants of 
control group (P=0.856).  
56 infants of studied group and 61 infants of 
control group were hospitalized in NICU 
after the birth. Thus there was no significant 
difference between two groups in terms of 
hospitalization in NICU (P=0.254). The 
infant hospitalization causes are shown in 
the Table II.  
56 infants of studied group and 61 infants of 
control group were passed away. So there 
was no significant difference between two 
groups in terms of the mortality rate among 
the infants born (P=0.294).  
The strong and subsequent initiation of 
uterine contractions with progressive 
cervical dilatation and effacement at 20-37 
weeks of pregnancy is defined as preterm 
labor and its prevalence has been reported as 
6-15% (5). Thus 25% of preterm labors 
occur after the premature rupture of 
membranes and 40-50% of them happen 
spontaneously (1).  
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Table I: Demographics finding of patients  
Group 
Case Control P 
Mother age 24.53 ± 
5.83 
24.89 ± 
5.48 0.709 
Gestational age 29.93 ± 
1.40 
29.77 ± 
1.52 0.526 
Baby count 1.91 ± 
1.33 
1.86 ± 
1.24 0.793 
Gravidity 0.63 ± 
1.13 
0.59 ± 
1.06 0.817 
Abortion count 0.29 ± 
0.76 
0.29 ± 
0.73 - 
1-minute 
Apgar score 
2.99 ± 
0.12 
2.80 ± 
0.40 <0.001 
5-minute 
Apgar score 
2.64 ± 
0.48 
2.63  ± 
0.49 0.862 
  
Table II: Causes of NICU admission of neonates  
Group 
Case Control P 
RDS 42 56 0.010 
NEC 26 19 0.205 
Sepsis 22 20 0.712 
IVH 1 2 - 
The preterm labor is responsible for almost 
75% of all neonatal deaths and 50% of 
childhood neurological complications (5-6) 
and it also leads to the prolonged 
hospitalization and increased hospital 
charges (7). Preterm labor with the 6-10% 
prevalence is the most common cause of 
prenatal mortality (8). Although its causes 
are almost unknown, in 50% of cases it is 
multi-factorial (9-10).  
Considering the importance of the subject 
and the increased prevalence of preterm 
labor in recent years, it is very critical to 
find a way to cure this disease. So the 
several studies provide different approaches 
in order to treat preterm labor based on its 
etiology (11).  
There is a wide range of therapeutic 
methods to prevent the progression of 
preterm labor which are in order to postpone 
the disease occurrence and reducing 
neonatal infection (12). 
In this study, we evaluated the effects of 
Indomethacin and magnesium sulfate to 
prevent preterm birth. Since the treatment of 
preterm labor and postpone it would 
increase the survival of newborns and could 
improve the quality of him/her life and also 
it would reduce the costs required for the 
care and cure of premature infants, so the 
tocolytics drugs such as magnesium sulfate 
and calcium channel blockers like 
Nifedipine are used to achieve this purpose 
(13).  
Nowadays, tocolytics are widely consumed 
and they are considered as the first-line of 
treatment (14). However, no tocolytics drugs 
-with complete efficacy and without any 
side effects- have been introduced. 
Therefore the researches are still being 
continued in order to provide the safe drugs 
for this serious problem (15).  
Magnesium sulfate and Terbutaline is used 
as the first line of treatment of the preterm 
labor and Nifedipine and Indomethacin are 
recommended in the cases which are more 
difficult and resistant to cure. Furthermore 
in some articles, they are presented as drugs 
which are preferred to the first line 
medicines (16). But it was not approved by 
the results of the other researches. It is noted 
that Indomethacin treatment is not effective 
for such problem so Further research is 
needed to confirm its impacts on preterm 
labor (17-18). Since there is no theoretical 
consensus regarding the administration of 
tocolytics so it should be empirically 
decided to choose a prepare treatment for 
this disease (19).  
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After finishing the necessary studies on the 
efficacy of Indomethacin, King and 
colleagues reported that this drug could 
further reduce the rate of preterm deliveries 
compared with placebo and magnesium 
sulfate (19-20). In our research, it has been 
also demonstrated that Indomethacin has 
beneficial effects on reducing preterm birth 
such as magnesium sulfate. There is no 
significant difference between the patients 
of two groups in terms of the physical 
conditions of the newborns and the infants at 
birth (P=0.294).  
In a research conducted by Lewis and 
colleagues on the 44 pregnant women with 
symptoms of preterm delivery, the synthetic 
efficacy of (Indomethacin + Magnesium 
Sulphate) was compared with the 
Magnesium Sulphate in order to postpone 
the preterm labor and It was indicated that 
the preterm labor delay in the patients who 
have consumed a combination of tocolytics 
drugs and the cases who have taken just a 
Magnesium Sulphate were respectively as 
368 hours and 71 hours (21).  
In our study, the average intervals between 
the start of pains and the true labor were 
respectively 83.01 ± 91.53 and 83.76 ± 
127.42 among the cases (Indomethacin) and 
control group So there was no significant 
difference in the average intervals between 
the onset of pains and the true labor among 
two groups(P=0.968).  
Whereas Indomethacin is a potent inhibitor 
of prostaglandin, so in some studies, it has 
been introduced as the most effective 
tocolytics drugs which has the most efficacy 
in order to the treatment of preterm labor 
(22). Potential effects of Indomethacin are 
superior to magnesium sulfate which is 
considered as a first line treatment; so it 
could inhibit the preterm labor more than 48 
hours (17). 
In Panther et al' research, it was indicated 
that the oral tocolytics Indomethacin could 
inhibit the preterm labor more than 48 hours 
in 81% of case while the placebo could stop 
this process more than 48 hours just in 56% 
of cases. This could be due to initial 
treatment with magnesium sulfate or 
Ritodrine and longer duration of 
Indomethacin (18). In our study, the delivery 
delay was more than 48 hours in 26 cases of 
the patient groups (Indomethacin) which 
was higher than the 22 cases of control 
group but this difference was not significant.   
Magnesium sulfate which is the first line 
treatment of preterm labor is widely used in 
obstetric services. The analysis of Amon and 
colleagues indicated that intravenous 
magnesium sulfate could delay the delivery 
about 24 48 hours, in 74 and 60 % of 
women (23). In our research, the magnesium 
sulfate led to a delay in preterm labor more 
than 24-48 hours in 32-60% of cases. 
In other study, the intravenous magnesium 
sulfate (initial dose: 6 grams, then 2 grams 
per hour) are less effective in delaying 
delivery compared with the oral Nicardipine 
(initial oral dose: 40 mg and then 20 mg per 
2 hours, maximum to 80 mg) (22). 
According to Makunz et al' analyses, the 
neonatal complications are higher in the 
Indomethacin group which is due to the lack 
of control over the confounding variables 
(17). Despite this fact that Pantr and 
colleagues mentioned to the two Necrotizing 
enterocolitis caused by Indomethacin, but 
this difference was not statistically 
significant (18).  
Conclusion  
In our research, it has been also 
demonstrated that Indomethacin has 
beneficial effects on reducing preterm birth 
such as magnesium sulfate. There is no 
significant difference between the patients 
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of two groups in terms of the physical 
conditions of the newborns and the infants at 
birth and there was no significant difference 
between the average intervals of the pains 
onset and the true labor. In our study, the 
magnesium sulfate led to a delay in preterm 
labor more than 24-48 hours in 32-60% of 
cases and in contrast, the Indomethacin led 
to a delay in this progress more than 24-48 
hours in 37-63% of cases. 
The apgar rate of infants in the 
Indomethacin group was significantly higher 
than in controls at the first second. There 
was no significant difference between the 
infants of both Indomethacin and control 
groups in terms of the apgar rate at the fifth 
seconds.   The infants' mortality rate and the 
hospitalization in NICU were similar in both 
methods.  
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